Published in Pharma Law Weekly, March 15th, 2005
In a recent study from Germany, "[g]enomic imbalances in 31 formalin-fixed and paraffin-embedded primary tumors of advanced breast cancer were analyzed by microarray-based comparative genomic hybridization (matrix-CGH)."
"A DNA chip was designed comprising 422 mapped genomic sequences including 47 proto-oncogenes, 15 tumor suppressor genes, as well as frequently imbalanced chromosomal regions," explained M. Nessling and coauthors at the Deutsches Krebsforschungszentrum in Heidelberg. "Analysis of the data was challenging due to the impaired quality of DNA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly